ARCHIVES

The NCI director and acting FDA commissioner called for faster approval of cancer drugs in speech to FDA staff.

This article is from The Cancer Letter archive.

Vol. 31 No. 38 | October 21, 2005

Download PDF Visit The Full Archive

Related Articles

NCAB Opposes Line Item for Centers

May 23, 1980

NCI Director Andrew von Eschenbach To Resign June 10, Remain As FDA Acting Commissioner.

June 2, 2006

Phase III Trial Demonstrates Early Docetaxel Combined With ADT Can Extend Survival

December 27, 2013

Program Project Scores Have Compressed Review Shuld Return To Rank Order; Broder

October 2, 1992

Neratinib Graduates from I-SPY Phase II Adaptive Trial Regimen

April 25, 2014

Regional Groups: Why 15 Were Not Among Those Funded; Cancer Regional Studies Review Committee Chartered

July 2, 1982